Abiopharma

🔍 Shah Neerav Dilip (Director)

Company: Arrive AI Inc. (ARAI)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 25,348 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 101,763.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 8,315 shares of Common Stock (Direct)
  Date: 2026-03-31 | Code: F | equity_swap_involved: 0 | shares_owned_after: 93,448.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 25,348 shares of Restricted Stock Award (Derivative)
  Date: 2026-03-31 | Code: M | equity_swap_involved: 0 | shares_owned_after: 50,698.00 | transaction_form_type: 4 | Footnotes: F2, F4
• Acquired 566,038 shares of Restricted Stock Award (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 566,038.00 | transaction_form_type: 4 | Footnotes: F3, F4

Footnotes:

• F1: These securities are vested shares from Restricted Stock Units (RSUs) which were granted on December 31, 2025. Amount shown represents vested shares of 25,348, less shares relinquished to cover taxes (8,315 shares). The shares have been issued pursuant to the Company's 2023 Equity Incentive Plan.
• F2: Represents the gross number of shares vesting from RSUs which were granted on December 31, 2025, and vested on March 31, 2026.
• F3: RSUs were granted on March 31, 2026, which vest as follows: (i) 188,678 shares on March 31, 2027; (ii) 188,680 shares on March 31, 2028; and (iii) 188,680 shares on March 31, 2029, subject to achievement of company performance objectives. The RSUs have been issued pursuant to the Company's 2023 Equity Incentive Plan.
• F4: The RSUs do not expire, they either vest or are canceled prior to vesting date.